9704 Medical Center Drive
Rockville, MD 20850
301 251 5172
Full Time Employees: 357
|Dr. Scott Koenig M.D., Ph.D.||Pres, CEO & Director||954.14k||N/A||1952|
|Mr. James Karrels||Sr. VP, CFO & Corp. Sec.||577.9k||115.53k||1967|
|Mr. Eric Blasius Risser||Chief Operating Officer||571.98k||N/A||1973|
|Dr. Thomas M. Spitznagel Ph.D.||Sr. VP of Technical Operations||550.97k||204.5k||1967|
|Dr. Ezio Bonvini||Sr. VP of Research & Chief Scientific Officer||612.21k||264.03k||1954|
|Mr. Jeffrey Stuart Peters||Sr. VP & Gen. Counsel||N/A||N/A||1972|
|Dr. Stephen L. Eck M.D., Ph.D.||Sr. VP of Clinical Devel. & Chief Medical Officer||N/A||N/A||1955|
|Ms. Lynn Cilinski||VP, Controller & Treasurer||N/A||N/A||1958|
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3;Retifanlimab, an monoclonal antibody used for cancer therapeutics; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
MacroGenics, Inc.’s ISS Governance QualityScore as of March 1, 2023 is 7. The pillar scores are Audit: 7; Board: 8; Shareholder Rights: 7; Compensation: 5.